When conventional medicine exhausts all standard possibilities, the only remaining option is to target the root cause of the disease. This is exactly what happened to Alyssa Tapley from Leicestershire, a British girl who in 2022 became the first person in the world to have her life saved by DNA base editing—a new technology that allows specific "letters" of the genetic code to be altered without breaking the double helix.
In May 2021, at the age of thirteen, Alyssa was diagnosed with T-cell acute lymphoblastic leukemia, one of the most aggressive forms of blood cancer. Before this, her parents had only noticed frequent colds, viral infections, and persistent fatigue. What initially seemed like typical childhood illnesses progressed rapidly, and the girl soon found herself in intensive care.
Doctors at hospitals in Leicester and Sheffield exhausted every available treatment at the time, including intensive chemotherapy, standard therapy protocols, and a bone marrow transplant. However, the disease returned just a few months later. Following the relapse, doctors candidly informed the family that no effective treatment options remained and that any further care could only be palliative.
But her parents refused to give up hope and continued searching for a chance at survival. This led the family to discover a clinical trial led by Professor Waseem Qasim at Great Ormond Street Hospital for Children in London. Researchers at the UCL Great Ormond Street Institute of Child Health were developing a completely new approach that had never before been tested on a human patient.
The treatment relied on genetically modified T-lymphocytes—immune cells engineered to recognize and destroy tumors. However, T-cell leukemia presented a significant challenge: standard modified cells would attack not only the cancer but also each other, as they were unable to distinguish between healthy and malignant T-lymphocytes.
The solution proved to be unexpected and revolutionary. Using base editing technology, researchers made several precise modifications to the genetic code of donor immune cells. Unlike the traditional CRISPR-Cas9 system, which cuts both strands of DNA, this method chemically converts one nitrogenous base into another. This approach significantly lowered the risk of unintended genomic alterations and enabled the creation of cells that could selectively destroy the tumor without harming each other or the patient's healthy tissue.
In May 2022, Alyssa was admitted to the bone marrow transplant unit at Great Ormond Street Hospital. She became the first patient in the world to receive this experimental therapy.
Before the treatment began, the young girl spoke words that would later resonate around the globe:
“Even if this doesn't help me, perhaps it will help someone else.”
Following a preparatory course of treatment, doctors administered the donor-derived, genetically edited T-lymphocytes. Within just a few days, these cells began to multiply rapidly throughout her body. Four weeks later, a bone marrow biopsy showed a state of complete remission, with cancer cells having vanished and no signs of minimal residual disease detectable. Subsequently, Alyssa received a second stem cell transplant to help rebuild her immune system.
Base editing technology was developed in 2016 by the laboratory of American biochemist David Liu. In just a few years, it progressed from a fundamental discovery to clinical application, proving that specific segments of DNA could be modified with high precision without compromising the double-helix structure.
Alyssa’s case proved to be more than just an isolated success. By the end of 2025, the trial had expanded to eleven patients, including Alyssa herself, eight other children, and two adults. According to data published in The New England Journal of Medicine and presented at the American Society of Hematology annual conference, 82% of participants achieved deep remission, enabling them to proceed to stem cell transplantation. Nearly two-thirds of the patients remain disease-free, with the first trial participants now surpassing three years without a relapse.
Today, Alyssa is sixteen years old. She is a student who travels, spends time with friends, attends concerts, and speaks at scientific conferences to share her journey. Only a few years ago, doctors were preparing her family for the worst. Now, she stands as a symbol of how scientific breakthroughs can fundamentally change human destiny.
Conclusion
Alyssa’s story represents more than just the success of a single experimental therapy. It demonstrates that base editing is moving beyond the laboratory and is gradually becoming a viable tool for clinical medicine. Should further research confirm the safety and efficacy of this method, it could transform the treatment of not only specific types of leukemia but also numerous hereditary disorders of the blood, immune system, and other organs.
Until quite recently, gene therapy was considered a distant prospect. Today, it is already saving lives. And it is possible that stories like this will signal the start of a new era in medicine, where doctors no longer simply manage the effects of a disease, but correct its underlying cause at the level of the DNA itself.
